Printer Friendly

Bulgarian Drug Maker Sopharma Starts Sales in Austria.

Bulgarian blue-chip drug company Sopharma has announced plans to start sales in Austria as part of its expansion plans.

Nivalin, a plant-based medicine that treats neurological diseases, has become the first Bulgarian medicine to be registered in Austria, a real breakthrough on what is considered to be one of the most conservative markets in Europe. In Austria the medicine has been registered under the trademark Nivaject.

The news comes nearly a year after the company announced plans to sell in the United States its anti-smoking drug Tabex, a Sopharma trademark. For this purpose the company became a shareholder in a newly set up US company Extab.

In order to distribute Tabex in the US, the company needs the approval of the most stringent drug regulator in the world, the Food and Drug Administration (FDA).
COPYRIGHT 2010 Novinite Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Sofia News Agency
Date:Apr 29, 2010
Words:134
Previous Article:Demand for Studio Flats in Bulgaria Expected to Increase.
Next Article:Bulgarian Torrent Tracking Sites Under Threat.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters